Expert Commentary

Managing menopausal symptoms in women with a BRCA mutation

OBG Manag. 2015 October;27(10)
By
Andrew M. Kaunitz, MD
Author and Disclosure Information

Dr. Andrew Kaunitz elaborates on data, presented at NAMS 2015, regarding the use of estrogen and estrogen-progestin in women undergoing risk-reducing gynecologic surgery. He offers his to-the-point advice for clinicians who are treating women with a BRCA mutation.

 

This audiocast was recorded at the North American Menopause Society Annual Meeting held September 30 to October 3, 2015, in Las Vegas, Nevada

For more on this topic, read Dr. Kaunitz's August 2015 Cases in Menopause article, Is menopausal hormone therapy safe when your patient carries a BRCA mutation?

Recommended Reading

ASCO: Many women with triple-negative breast cancer aren’t screened for BRCA
Breast Cancer ICYMI
ASCO: Neoadjuvant chemo does not increase breast cancer surgery complications
Breast Cancer ICYMI
ASCO: Potentially targetable biomarkers identified in geriatric breast cancer tumors
Breast Cancer ICYMI
Computer-aided detection fails to improve mammographic accuracy
Breast Cancer ICYMI
Two heads plus four hands equal safe, shorter bilateral mastectomies
Breast Cancer ICYMI
Dose-dense breast chemotherapy is also cost dense
Breast Cancer ICYMI
Positive lumpectomy margin risk rises with breast density
Breast Cancer ICYMI
Nipple-sparing mastectomy feasible in N+ early breast cancer
Breast Cancer ICYMI
Get smart about dense breasts
Breast Cancer ICYMI
VIDEO: When to use MRI in breast cancer
Breast Cancer ICYMI

Related Articles